Treatment Intensification in Type 2 Diabetes: 3 Cases

Slideshow

When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?

Choice of antihyperglycemic agent after metformin can now be selected to also address comorbidites often seen in T2DM patients. Each of the 3 patients in this short case quiz presents a challenge as well as an opportonity to optimize diabetes care.  

Recent Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes / Image credit: ©Argus/AdobeStock

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

Sydney Jennings
December 23rd 2024
Article

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 14th 2024
Article

Your daily dose of the clinical news you may have missed.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 5th 2024
Article

Your daily dose of the clinical news you may have missed.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

Sydney Jennings
November 1st 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.